Press Releases and Statements

Browse Press Releases and Statements Content

WASHINGTON, D.C. – Consumer Healthcare Products Association (CHPA) President and CEO Scott Melville released the below statement today following the U.S. House of Representatives passing H.R. 7024, the Tax Relief for American Families and Workers Act., a bipartisan, bicameral tax package that will expand the child tax credit and increase depreciation allowances to promote economic innovation and growth.

Jan 31, 2024

Congressmen Curtis, Cárdenas Spearhead Effort

Jan 29, 2024

WASHINGTON, D.C. — CHPA Senior Vice President of Dietary Supplements Duffy MacKay released the following statement in response to results from a recent trial published in the American Journal of Clinical Nutrition (AJCN), finding that adults ages 60 and older who took a daily multivitamin (MVM) showed a “significantly more favorable change in episodic memory,” reducing cognitive aging by two years compared to those who took the placebo. These results mark the third time a MVM clinical trial within the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) has confirmed the positive benefits MVM’s have on older adults’ cognitive health.

Jan 23, 2024

Consumer Healthcare Products Association (CHPA) Vice President of Regulatory & Scientific Affairs Jay Sirois, PhD released the following statement today following the publication of a paper, Safety Considerations for Dietary Supplement Manufacturers in the United States, which he recently co-authored alongside several CHPA manufacturers in the Journal of Regulatory Toxicology and Pharmacology:

Jan 16, 2024

Washington, D.C. – The annual Monitoring the Future survey (MTF), conducted by researchers at the University of Michigan and funded by the National Institute on Drug Abuse (NIDA), shows that the percentage of adolescents reporting any substance use in 2023 continues to “hold steady” and remains below pre-pandemic levels, including abuse of over-the-counter (OTC) cough & cold medicines.

Dec 15, 2023

(PHILADELPHIA) – The Consumer Healthcare Products Association Educational Foundation (CHPAEF) held its 8th Annual Gala last night at The Bellevue Hotel in Philadelphia. The widely attended event brought together more than 350 attendees from 93 companies across the self-care industry. In addition to highlighting CHPAEF’s key 2023 educational initiatives, the event program also included the unveiling of the Foundation’s new name: Health in Hand, and an announcement on the election of Elizabeth Karvonen, Team Lead of the Emerson Group, to serve as Health in Hand’s new board chair. Elizabeth will succeed previous chair Kyle Stenzel, Senior Vice President of Sales and Global Supply Chain for Combe Inc.

Nov 16, 2023

“After urging Governor Hochul to recognize the importance of a more balanced approach to this issue, CHPA was disappointed to see this legislation signed into law today, making New York the only state in the country to unnecessarily limit consumers’ access to a broad range of dietary supplements.

Oct 25, 2023

(Washington, D.C.) – Consumer Healthcare Products Association (CHPA) Senior Vice President of Regulatory and Scientific Affairs Lisa Parks released the following statement today regarding the U.S. Food and Drug Administration’s

Sep 28, 2023

This week, the Consumer Healthcare Products Association (CHPA) hosted its annual Regulatory, Scientific & Quality (RSQ) Conference. This year’s premier gathering of regulatory experts in the consumer healthcare industry was attended by more than 300 participants and included over 60 speakers and panelists.

Sep 20, 2023

CHPA released a statement after submitting a Citizen Petition to the U.S. Federal Trade Commission (FTC) urging it to withdraw the Notice of Penalty Offenses Concerning Substantiation of Product Claims.

Sep 15, 2023

CHPA expresses disappointment in the recent NDAC recommendation and encourages FDA to consider the total weight of evidence before making any regulatory changes.

Sep 12, 2023

CHPA's most current statement on the recent meeting of the FDA Nonprescription Advisory Committee (NDAC) to evaluate the efficacy of oral phenylephrine (PE).

Sep 7, 2023

Filter Results